SV2014004804A - Composiciones de acciã“n prolongada - Google Patents

Composiciones de acciã“n prolongada

Info

Publication number
SV2014004804A
SV2014004804A SV2014004804A SV2014004804A SV2014004804A SV 2014004804 A SV2014004804 A SV 2014004804A SV 2014004804 A SV2014004804 A SV 2014004804A SV 2014004804 A SV2014004804 A SV 2014004804A SV 2014004804 A SV2014004804 A SV 2014004804A
Authority
SV
El Salvador
Prior art keywords
prolonged action
action compositions
composition
compositions
includer
Prior art date
Application number
SV2014004804A
Other languages
English (en)
Inventor
Alawi Fadil Al
Karthigeyan Nanjan
Original Assignee
Bayer New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49161532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2014004804(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer New Zealand Ltd filed Critical Bayer New Zealand Ltd
Publication of SV2014004804A publication Critical patent/SV2014004804A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LA PRESENTE INVENCIÓN HACE REFERENCIA A UNA COMPOSICIÓN DE ACCIÓN PROLONGADA PARA TRATAR UN ANIMAL QUE REQUIERE TRATAMIENTO Y QUE INCLUYE UNA CANTIDAD TERAPÉUTICAMENTE EFICAZ DE UN AGENTE BIOACTIVO, CARACTERIZADA PORQUE LA COMPOSICIÓN INCLUYE UN PORTADOR NO ACUOSO Y UN SISTEMA SOLVENTE QUE COMPRENDE ACEITE DE RICINO Y AL MENOS UNA AMIDA C�CLICA
SV2014004804A 2012-03-13 2014-09-10 Composiciones de acciã“n prolongada SV2014004804A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ59875712 2012-03-13
PCT/NZ2013/000036 WO2013137748A1 (en) 2012-03-13 2013-03-13 Long acting compositions

Publications (1)

Publication Number Publication Date
SV2014004804A true SV2014004804A (es) 2017-04-20

Family

ID=49161532

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2014004804A SV2014004804A (es) 2012-03-13 2014-09-10 Composiciones de acciã“n prolongada

Country Status (20)

Country Link
US (1) US9616044B2 (es)
EP (1) EP2825154A4 (es)
JP (1) JP6273252B2 (es)
KR (1) KR20140136005A (es)
CN (1) CN104168886A (es)
AU (1) AU2013201479C1 (es)
CA (1) CA2867079A1 (es)
CL (1) CL2014002401A1 (es)
CO (1) CO7071132A2 (es)
CR (1) CR20140423A (es)
DO (1) DOP2014000207A (es)
IL (1) IL234597A0 (es)
MX (1) MX354966B (es)
NI (1) NI201400106A (es)
PE (1) PE20142279A1 (es)
PH (1) PH12014502016B1 (es)
RU (1) RU2014141088A (es)
SV (1) SV2014004804A (es)
WO (1) WO2013137748A1 (es)
ZA (1) ZA201406753B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUB20153652A1 (it) 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169846A (en) * 1989-10-12 1992-12-08 Crooks Michael J Non-aqueous micellar solutions of anthelmintic benzimidazoles, closantel, or phenothiazine, and insect growth regulators
DK0535734T3 (da) * 1991-09-30 1999-08-09 Merck & Co Inc Langtidsvirkende injicerbare formuleringer indeholdende hydrogeneret castorolie
DE19520275A1 (de) 1995-06-02 1996-12-05 Bayer Ag Endoparasitizide Mittel
AU713580B2 (en) 1995-09-25 1999-12-02 Merial Ltd Anthelmintic macrocyclic lactone compositions
DE19613972A1 (de) 1996-04-09 1997-10-16 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl
DE19638045A1 (de) * 1996-09-18 1998-03-19 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen
US6998131B2 (en) * 1996-09-19 2006-02-14 Merial Limited Spot-on formulations for combating parasites
GB9815801D0 (en) * 1998-07-21 1998-09-16 Merck & Co Inc Liquid polymeric compositions for controlled released bioactive substances
CN1130990C (zh) 1999-11-02 2003-12-17 王毅远 一种纯天然方便食品及其制造方法
US6340672B1 (en) 2000-02-16 2002-01-22 Phoenix Scientific, Inc. Parasiticidal formulation and a method of making this formulation
AU781682B2 (en) 2000-03-20 2005-06-09 Zoetis Services Llc Sustained-release compositions for parenteral administration
CN1383821A (zh) 2001-03-16 2002-12-11 王玉万 一种含丙硫苯咪唑亚砜或其盐类的兽用注射剂
AU2002100152A4 (en) * 2002-02-28 2002-04-11 Jurox Pty Ltd Parasiticide composition
US7001889B2 (en) * 2002-06-21 2006-02-21 Merial Limited Anthelmintic oral homogeneous veterinary pastes
US6653288B1 (en) * 2002-09-30 2003-11-25 Virbac S.A. Injectable anthelmintic compositions and methods for using same
CN1490009A (zh) * 2002-10-17 2004-04-21 王玉万 含抗球虫药物的缓释注射剂
US20060257440A1 (en) * 2003-05-19 2006-11-16 Makoto Asai Insecticidal composition
NZ535644A (en) 2003-07-25 2007-05-31 Ashmont Holdings Ltd Anthelmintic formulations
CN1293921C (zh) 2003-08-18 2007-01-10 王玉万 含乙基纤维素和脂肪酸酯类的长效注射剂
TR200601608T1 (tr) 2003-10-17 2006-12-21 Akzo Nobel N.V Bir avermektin kombinasyonu içeren uzun süre etkili bileşimler.
AU2005100403B4 (en) * 2005-05-13 2005-09-01 Jurox Pty Ltd Parasiticide Composition
BRPI0800259A2 (pt) * 2008-02-27 2011-05-31 Noxon Do Brasil Quimica E Farmaceutica Ltda formulações veterinárias compreendendo lactonas macrocìclicas e minerais, seus usos na preparação de produtos veterinários e métodos de ganho de produtividade e tratamento e/ou profilaxia de doenças causadas por agentes biológicos nocivos à saúde animal
AU2009271299B2 (en) 2008-06-24 2014-09-11 Boehringer Ingelheim Animal Health USA Inc. Anthelminthic formulations
MX2009001235A (es) * 2008-09-19 2010-04-29 Agrovet Market S A Composicion y uso de un gel oral endoparasiticida bioadhesivo de larga accion a base de doramectina.
EP2396006B1 (en) * 2009-02-16 2012-12-19 Pfizer Inc. High dosage doramectin formulation
CN101703776B (zh) * 2009-09-28 2012-07-11 洛阳惠中兽药有限公司 一种抗感染剂长效注射液的制备方法
BRPI1001224A2 (pt) 2010-04-07 2011-03-15 Clarion Biociencias Ltda processo de fabricação de formulação injetável a base de fluazuron associado a avermectinas para o controle e prevenção de endo e ectoparasitas em animais domésticos
CN103260620A (zh) * 2010-12-27 2013-08-21 英特维特国际股份有限公司 包含三缩四乙二醇的外用局部异噁唑啉制剂

Also Published As

Publication number Publication date
EP2825154A4 (en) 2015-11-11
KR20140136005A (ko) 2014-11-27
CO7071132A2 (es) 2014-09-30
NI201400106A (es) 2015-01-14
EP2825154A1 (en) 2015-01-21
AU2013201479A1 (en) 2013-10-03
PH12014502016A1 (en) 2014-11-24
JP6273252B2 (ja) 2018-01-31
CR20140423A (es) 2014-10-20
CL2014002401A1 (es) 2015-04-17
PE20142279A1 (es) 2015-01-25
AU2013201479C1 (en) 2017-11-09
US20150038565A1 (en) 2015-02-05
MX2014010957A (es) 2014-10-13
CA2867079A1 (en) 2013-09-19
AU2013201479B2 (en) 2015-07-02
JP2015509978A (ja) 2015-04-02
WO2013137748A1 (en) 2013-09-19
DOP2014000207A (es) 2014-11-30
US9616044B2 (en) 2017-04-11
ZA201406753B (en) 2015-12-23
RU2014141088A (ru) 2016-05-10
CN104168886A (zh) 2014-11-26
PH12014502016B1 (en) 2014-11-24
IL234597A0 (en) 2014-11-30
MX354966B (es) 2018-03-27

Similar Documents

Publication Publication Date Title
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
CL2015000699A1 (es) Métodos para tratamiento de cáncer.
ECSP12012097A (es) Derivados de fumarato de ácido graso y sus usos
EA201591340A1 (ru) Модулятор андрогенного рецептора и его применения
BR112013017154A8 (pt) Uso de fitocanabinóide canabidiol (cbd) em combinação com um fármaco antiepiléptico padrão (saed) no tratamento de epilepsia
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
BR112017027147A2 (pt) agente estimulante de restauração/crescimento de cabelo
BR112015023203A2 (pt) métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos
BR112016007946A2 (pt) combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
DOP2016000253A (es) Nuevos compuestos
BRPI0911031B8 (pt) compostos de piperidina ligada do tipo quinoxalina substituídos e os usos destes
ECSP19057403A (es) Usos terapéuticos de un polvo de insectos
BR112018013063A2 (pt) combinação terapêutica inibidora de bromodomínio e proteína extra-terminal
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112018001435A2 (pt) métodos para entrega linfática de agentes ativos
BR112016013116A8 (pt) inibidores de trifluorometil pirazolil guanidina f1f0-atpase, seus usos, e composições farmacêuticas
BR112015024860A2 (pt) vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose
CR20110226A (es) Composición para tratar enfermedad
CR10524A (es) Compuesto triciclico y uso farmaceutico del mismo
BR112016012248A2 (pt) método de tratamento de nefropatia
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt